S&P 500   4,349.75 (+0.46%)
DOW   34,116.07 (+0.13%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.13 (-0.22%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.24 (+4.91%)
AMD   98.26 (+2.24%)
T   15.10 (-1.37%)
F   12.56 (+2.95%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.87 (-0.11%)
DIS   82.28 (-0.54%)
AMC   7.92 (+2.86%)
PFE   32.81 (-0.12%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
S&P 500   4,349.75 (+0.46%)
DOW   34,116.07 (+0.13%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.13 (-0.22%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.24 (+4.91%)
AMD   98.26 (+2.24%)
T   15.10 (-1.37%)
F   12.56 (+2.95%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.87 (-0.11%)
DIS   82.28 (-0.54%)
AMC   7.92 (+2.86%)
PFE   32.81 (-0.12%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
S&P 500   4,349.75 (+0.46%)
DOW   34,116.07 (+0.13%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.13 (-0.22%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.24 (+4.91%)
AMD   98.26 (+2.24%)
T   15.10 (-1.37%)
F   12.56 (+2.95%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.87 (-0.11%)
DIS   82.28 (-0.54%)
AMC   7.92 (+2.86%)
PFE   32.81 (-0.12%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
S&P 500   4,349.75 (+0.46%)
DOW   34,116.07 (+0.13%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.13 (-0.22%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.24 (+4.91%)
AMD   98.26 (+2.24%)
T   15.10 (-1.37%)
F   12.56 (+2.95%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.87 (-0.11%)
DIS   82.28 (-0.54%)
AMC   7.92 (+2.86%)
PFE   32.81 (-0.12%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Forecast, Price & News

$27.83
+0.16 (+0.58%)
(As of 11:36 AM ET)
Compare
Today's Range
$27.67
$28.18
50-Day Range
$27.67
$40.81
52-Week Range
$27.39
$44.09
Volume
69,961 shs
Average Volume
218,035 shs
Market Capitalization
$832.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.33

Fulgent Genetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
53.0% Upside
$42.33 Price Target
Short Interest
Healthy
3.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.36mentions of Fulgent Genetics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$542,598 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.10) to ($1.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

219th out of 965 stocks

Medical Laboratories Industry

6th out of 24 stocks


FLGT stock logo

About Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

FLGT Price History

FLGT Stock News Headlines

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie Sells 1,492 Shares
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Q2 2023 Fulgent Genetics Inc Earnings Call
Fulgent Reports Second Quarter 2023 Financial Results
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Fulgent Genetics Q2 2023 Earnings Preview
FLGT - Fulgent Genetics, Inc.
Fulgent Genetics Inc FLGT Stock Quote
See More Headlines
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Company Calendar

Last Earnings
8/04/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLGT
Employees
1,012
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$42.33
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+53.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$143.40 million
Pretax Margin
-21.94%

Debt

Sales & Book Value

Annual Sales
$618.97 million
Cash Flow
$6.53 per share
Book Value
$43.14 per share

Miscellaneous

Free Float
20,422,000
Market Cap
$828.16 million
Optionable
Not Optionable
Beta
1.52

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Ming HsiehMr. Ming Hsieh (Age 67)
    Chairman & CEO
    Comp: $1.66M
  • Mr. Jian Xie (Age 57)
    COO & Pres
    Comp: $755.73k
  • Mr. Paul KimMr. Paul Kim (Age 56)
    Chief Financial Officer
    Comp: $757.59k
  • Dr. Han Lin Gao D.A.B.M.G. (Age 56)
    F.A.C.M.G., FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director
    Comp: $630.61k
  • Ms. Natalie Prescott
    VP & Gen. Counsel
  • Ms. Doreen Ng
    VP of Operations & Compliance and GM of Houston Office
  • Mr. Jakub Sram
    VP of Bus. Devel. & Sales
  • Ms. Ellen Tsui
    VP of HR
  • Mr. Brandon Perthuis
    Chief Commercial Officer
  • Dr. Lawrence M. Weiss M.D. (Age 66)
    Chief Medical Officer













FLGT Stock - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FLGT shares.
View FLGT analyst ratings
or view top-rated stocks.

What is Fulgent Genetics' stock price forecast for 2023?

3 brokers have issued 1 year price targets for Fulgent Genetics' stock. Their FLGT share price forecasts range from $37.00 to $45.00. On average, they expect the company's stock price to reach $42.33 in the next year. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for FLGT
or view top-rated stocks among Wall Street analysts.

How have FLGT shares performed in 2023?

Fulgent Genetics' stock was trading at $29.78 at the start of the year. Since then, FLGT shares have decreased by 7.1% and is now trading at $27.67.
View the best growth stocks for 2023 here
.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 597,900 shares, an increase of 9.2% from the August 15th total of 547,400 shares. Based on an average daily trading volume, of 210,500 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.2% of the shares of the company are short sold.
View Fulgent Genetics' Short Interest
.

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FLGT earnings forecast
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Friday, August, 4th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.26. The company earned $67.85 million during the quarter, compared to analyst estimates of $62.68 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 3.29% and a negative net margin of 15.84%.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY 2023 earnings guidance on Friday, August, 4th. The company provided EPS guidance of -$0.95--$0.95 for the period, compared to the consensus estimate of -$0.34. The company issued revenue guidance of -.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.13%), Dimensional Fund Advisors LP (3.50%), State Street Corp (2.53%), Nuveen Asset Management LLC (1.38%), Nuveen Asset Management LLC (1.38%) and Geode Capital Management LLC (1.38%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends
.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $27.67.

How much money does Fulgent Genetics make?

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $828.16 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Fulgent Genetics have?

The company employs 1,012 workers across the globe.

Does Fulgent Genetics have any subsidiaries?
The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.

This page (NASDAQ:FLGT) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -